Viracta Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Viracta Therapeutics

08/03/2024 12:56

* Viracta Therapeutics Inc  VIRX.OQ   VIRX.O  is expected
to show
no change in quarterly revenue when it reports  results on May 6
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Viracta Therapeutics Inc
is
for a loss of 29 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $5.50​, above​ its last closing price
of $0.81. ​​​

This summary was machine generated March 8 at 12:56 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)